Scarica l'app Stockscreener
29.00
0.14%
-0.04
Dopo l'orario di chiusura:
29.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$29.04
Aprire:
$28.94
Volume 24 ore:
1.63M
Relative Volume:
0.71
Capitalizzazione di mercato:
$3.55B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-7.398
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+0.10%
1M Prestazione:
-1.46%
6M Prestazione:
+110.76%
1 anno Prestazione:
+99.18%
Intervallo 1D:
$28.49
$29.88
Intervallo di 1 settimana:
$27.71
$29.88
Portata 52W:
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
29.00 | 3.56B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - ts2.tech
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Why Arcutis Biotherapeutics Inc. stock remains resilientRate Cut & Weekly Watchlist of Top Performers - Улправда
Perpetual Ltd Increases Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics Inc. stock gain from strong economyJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance Australia
Is Arcutis Biotherapeutics Inc. stock attractive for growth ETFsJuly 2025 EndofMonth & Momentum Based Trading Ideas - DonanımHaber
Price Action: Why Arcutis Biotherapeutics Inc. stock remains resilientJuly 2025 Review & Low Risk Entry Point Tips - Улправда
Investor Mood: What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Selloffs & Weekly Setup with ROI Potential - Улправда
What Wall Street predicts for Arcutis Biotherapeutics Inc. stock priceJuly 2025 Spike Watch & Detailed Earnings Play Alerts - Улправда
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesMarket Movers & Low Drawdown Investment Ideas - Улправда
Squarepoint Ops LLC Has $2.35 Million Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 11,500 Shares of Stock - MarketBeat
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Sahm
Arcutis Biotherapeutics Executive Sells Shares - TradingView — Track All Markets
Arcutis Biotherapeutics Insider Sold Shares Worth $332,851, According to a Recent SEC Filing - marketscreener.com
VP Burnett Sells 11,500 ($332.9K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView — Track All Markets
Arcutis (ARQT) CMO exercises options, sells 11,500 shares in plan trade - Stock Titan
This Biotech Stock Could Cure Your Portfolio's Pain - Finviz
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals - Yahoo Finance
Arcutis Biotherapeutics, Inc. $ARQT Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Gilder Gagnon Howe & Co. LLC Purchases 59,712 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Eczema awareness campaign launched by actress Tori Spelling and Dr. Adam Friedman - KOKH
ARQT (Arcutis Biotherapeutics) OCF Margin % : -1.77% (As of Sep. 2025) - GuruFocus
Tori Spelling Teams Up with Arcutis to Share Her Family’s Eczema Journey - WKEF
Norges Bank Takes $2.45 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? - sharewise.com
Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.7%What's Next? - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace
Arcutis Biotherapeutics Appoints Amit Munshi as New Director - TipRanks
Amit Munshi joins Arcutis board as founder Chaudhuri retires - Investing.com
Arcutis Biotherapeutics Announces Board Changes - TradingView — Track All Markets
Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India
Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com
Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcutis Biotherapeutics Inc Azioni (ARQT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Burnett Patrick | See Remarks |
Dec 15 '25 |
Option Exercise |
3.64 |
11,500 |
41,860 |
109,807 |
| Burnett Patrick | See Remarks |
Dec 15 '25 |
Sale |
28.94 |
11,500 |
332,851 |
98,307 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):